Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto plus pani) versus investigator's choice of therapy for G12C-mutated metastatic colorectal cancer (mCRC) - Fakih, M; Salvatore, L; Esaki, T (Journal of Clinical Oncology, 2024)